Blood test could replace kidney biopsy for common kidney disease?
NCT ID NCT07295808
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at blood and kidney tissue from 150 adults with IgA nephropathy or related kidney diseases. Researchers want to find unique patterns in immune cells that cause kidney damage. The goal is to develop a blood test that could diagnose the disease without a painful kidney biopsy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test to diagnose IgA nephropathy, reducing the need for invasive kidney biopsies.
- What could go wrong
- This is an early observational study, not a treatment trial. It may not find reliable markers, and any future test would require much more research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Jul 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients of interest: all patients with IgA nephropathy or rheumatoid purpura aged 18 years or older whose treatment requires a renal biopsy * Control patients: all patients with a renal disease other than IgA nephropathy or rheumatoid purpura whose treatment requires a renal biopsy Exclusion Criteria: * Patient opposition * Persons under legal guardianship * Persons whose psychological health prevents the collection of non-opposition
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IgA vasculitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Chu Limoges
RECRUITINGLimoges, 87042, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can digital tools and training help more kidney patients get transplants?
- Could your bone health decide if a dental implant lasts?
- Can a simple foot pump ease leg swelling in hospital patients?
- Could your blood type predict kidney treatment success?
- Can community hospitals in zambia master severe disease care?
- Can an ancient herbal remedy soothe the aftermath of stone surgery?